In January 2024, CureQ held its inaugural General Assembly in the beautiful Amrath hotel, Amsterdam. This marked an important milestone in the project. This gathering brought a chance to bring together all stakeholders, including researchers, companies, and patient organisations, and present our progress to the CureQ Advisory Board. Their feedback and perspective are incredibly valuable as we move forward.
Throughout this first pivotal year (2023), CureQ achieved several key accomplishments:
- Recruitment of Young Scientists: Talented young researchers were recruited from universities and applied sciences institutions, infusing the project with fresh perspectives and energy.
- Work Package Meetings and Team Building: Regular work package meetings were conducted alongside exclusive team-building workshops, enhancing cohesion and collaboration among the recruited scientists.
- Engagement with Patient Foundations: Presentations were delivered to patient foundations, strengthening ties with the patient community and emphasizing CureQ’s commitment to patient-centric research.
The Advisory Board highlighted that CureQ uniquely integrates all organizations and locations related to Huntington’s Disease (HD) and Spinocerebellar Ataxia (SCA), encompassing a wide range of disciplines and age groups. This underscores the consortium’s exceptional nature and the positive spirit driving its initiatives.
